Private Capital Group’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Private Capital Group’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	$2K	Hold	55	–	–	﹤0.01%	1609
2022 Q1	$3K	Sell	55 -17	-24%	-$816	﹤0.01%	1727
2021 Q4	$4K	Buy	72 +8	+13%	+$415	﹤0.01%	1645
2021 Q3	$4K	Sell	64 -48	-43%	-$2.36K	﹤0.01%	1691
2021 Q2	$5K	Buy	112 +54	+93%	+$2.23K	﹤0.01%	1580
2021 Q1	$2K	Buy	58 +48	+480%	+$2.23K	﹤0.01%	1809
2020 Q4	$1K	Buy	+10	New	+$468	﹤0.01%	1988
2020 Q3	–	Sell	-125	Closed	-$6K	–	2132
2020 Q2	$6K	Sell	125 -33	-21%	-$1.65K	﹤0.01%	1486
2020 Q1	$7K	Buy	+158	New	+$7.93K	﹤0.01%	1408

Other funds holding EGRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $130B AUM 46.38% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Private Capital Group's EGRX Position: Q2 2022 in Review

Private Capital Group held its Eagle Pharmaceuticals, Inc. (EGRX) position steady in Q2 2022 at 55 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1609.

Private Capital Group first reported a position in EGRX in Q1 2020 and has held it in 9 quarters since. The position peaked at $7K in Q1 2020. 163 funds tracked by Wall St. Rank hold EGRX as of Q2 2022.

Private Capital Group held 55 shares of Eagle Pharmaceuticals, Inc. worth $2K as of Q2 2022.
Private Capital Group left its Eagle Pharmaceuticals, Inc. share count unchanged in Q2 2022.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Private Capital Group's portfolio in Q2 2022, its #1609 holding.
Private Capital Group first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2020 and has held it in 9 quarters since.
Private Capital Group's Eagle Pharmaceuticals, Inc. position peaked at $7K in Q1 2020.
163 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2022.

Based on Private Capital Group's 13F filing for Q2 2022, filed 28 Jul 2022.